Mammalian cell-derived somatropin: A review of its use in the management of HIV-associated wasting

Drugs

Volumn 66, Issue 3, 2006, Pages 387-401

  Goldsmith, David R ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

HIV associated wasting; Pharmacodynamics; Pharmacokinetics; Somatropin; Therapeutic use

Indexed keywords

ANTIRETROVIRUS AGENT; DRONABINOL; HUMAN GROWTH HORMONE; MEGESTROL; NANDROLONE DECANOATE; OXANDROLONE; OXYMETHOLONE; PLACEBO; GROWTH HORMONE; RECOMBINANT PROTEIN;

ADVERSE OUTCOME; ARTHRALGIA; BODY COMPOSITION; BODY FAT; BODY WEIGHT; BRONCHITIS; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DATA BASE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERGOMETRY; FATIGUE; GENERALIZED EDEMA; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GYNECOMASTIA; HEADACHE; HEALTH STATUS; HEMATOPOIESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; IMMUNE FUNCTION TEST; IMMUNOSTIMULATION; INSOMNIA; KIDNEY CLEARANCE; KIDNEY METABOLISM; LEAN BODY WEIGHT; MAMMAL CELL; MYALGIA; NAUSEA; OSTEOARTHRITIS; PARESTHESIA; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; RHINITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; WASTING SYNDROME; WEIGHT REDUCTION; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; ENERGY METABOLISM; GENETICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

MAMMALIA;

BODY COMPOSITION; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; ENERGY METABOLISM; GROWTH HORMONE; HIV WASTING SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 33746061307     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666030-00014     Document Type: Review

References (54)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36 Suppl.: 1-15S
2. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000 Apr; 75 (4): 386-94
3. Perry CM, Wagstaff AJ. Recombinant mammalian cell-derived somatropin: a review of its pharmacological properties and therapeutic potential in the management of wasting associated with HIV infection. Biodrugs 1997; 8 (5): 394-414
4. Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 2003 Apr 1; 36 Suppl. 2: S69-78
5. Wanke C. Pathogenesis and consequences of HIV-associated wasting. J Acquir Immune Defic Syndr 2004 Dec; 37 Suppl. 5: S277-9
6. Polsky B, Kotler D, Steinhart C. Treatment guidelines for HIV-associated wasting. HIV Clin Trials 2004; 5 (1): 50-61
7. Tang AM, Jacobson DL, Spiegelman D, et al. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 2005 Sep; 40 (1): 70-6
8. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13 (14): 1933-42
9. Moyle GJ, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004 Apr 1; 35 (4): 367-75
10. Grinspoon S, Gelato M. The rational use of growth hormone in HIV-infected patients. J Clin Endocrinol Metab 2001 Aug; 86 (8): 3478-9
11. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993 Oct; 77 (4): 956-62
12. Mulligan K, Tai VW, Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting: a clinical research center study. J Clin Endocrinol Metab 1998 May; 83 (5): 1542-7
13. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996 Dec 1; 125 (11): 873-82
14. Berger DS, LaMarca A, Landy H, et al. A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting [abstract no. Mo.B.422]. Proceedings of the 11th International Conference on AIDS; 1996 Jul 9-12; Vancouver, 26
15. Paton NI, Newton PJ, Sharpstone DR, et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 1999 Jul 9; 13 (10): 1195-202
16. Serono International SA. Serostim®. Recombinant human growth hormone (r-hGH, somatropin). Study GF 9037: integrated clinical and statistical final report. Data on file. 2002 Aug 8
17. Laurence J, Grimison B, Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 1992 Jan 15; 79 (2): 467-72
18. Serono Inc. Serostim [somatropin (rDNA origin) for injection] prescribing information [online]. Available from URL: http://www.aidswasting.com [Accessed 2003 Dec 3]
19. Imami N, Pires A, Moyle G, et al. Growth hormone therapy induces HIV-1-specific CD4 and CD8 T cell responses in HAART treated patients [abstract no. ThPeA7090]. Proceedings of the 14th International Aids Conference; 2002 Jul 7-12; Barcelona, 357
20. Nguyen BY, Clerici M, Venzon DJ, et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998 May 28; 12 (8): 895-904
21. Smith KY, Wang R, Bosch RJ, et al. Treatment with growth hormone leads to improvement in total and naive CD4 lymphocyte recovery in HIV-infected subjects with incomplete immune reconstitution on HAART: preliminary results ACTG 5174 [abstract no. TuOa0203 plus poster]. Proceedings of the third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24-27; Rio de Janeiro
22. Denny TN, Landy H, Breitmeyer JB. Immunomodulatory effects of mammalian cell-derived human recombinant growth hormone (r-hGH[m]) in patients with AIDS wasting [abstract no. 317]. Proceedings of the third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington, DC, 112
23. Zeisel HJ, von Petrykowski W, Wais U. Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Horm Res 1992; 37 Suppl. 2: 5-13
24. Murray FT, Wright GJ, Landy H, et al. Comparative bioequivalence and patient acceptance of recombinant human growth hormone administered by a needle-free device (SeroJet)[TM]) or standard syringe injection. Today's Therapeutic Trends 2001; 19 (3): 137-55
25. Serono Laboratories Inc. Serostim [somatropin (rDNA origin) for injection] product monograph. 1999
26. Desyatnik M, Baaj A. Cost-effectiveness analysis of serostim versus oxandrin in the treatment of AIDS wasting syndrome [abstract no. MoPeC2477]. Proceedings of the 13th International Aids Conference; 2000 Jul 9-14; Durban, 146-7
27. Baaj A, Desyatnik M. Cost effectiveness of serostim versus megace in the treatment of AIDS wasting syndrome [abstract no. Mo PeC2478]. Proceedings of the 13th International AIDS Conference; 2000 Jul 9-14; Durban, 147
28. Cafaro V, de Guzman C, Gary D, et al. Cost outcomes for HIV-associated wasting: initial treatment with somatropin vs. initial treatment with other wasting treatments [abstract no. MoP238]. Clin Microbiol Infect 2000; 6 Suppl. 1: 194
29. Wanke C, Kotler D. Collaborative recommendations: the approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr 2004 Dec; 37 Suppl. 5: S284-8
30. Kotler D. Challenges to diagnosis of HIV-associated wasting. J Acquir Immune Defic Syndr 2004 Dec; 37 Suppl. 5: S280-3
31. Daar E, Gaccione P, Muurahainen N, et al. Gains in lean body mass (LBM) and not body fat are associated with improved survival in patients with AIDS wasting (AW) [abstract no. P151]. AIDS 2000; 14 Suppl. 4: S60
32. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. Aids Patient Care STDS 2001 Aug; 15 (8): 411-23
33. Suttmann U, Ockenga J, Selberg O, et al. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr 1995; 8 (3): 239-46
34. Schwenk A, Beisenherz A, Romer K, et al. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active aniretroviral treatment. Am J Clin Nutr 2000; 72: 496-501
35. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (1): 80-5
36. Tang AM, Forrester J, Spiegelman D, et al. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002 Oct 1; 31 (2): 230-6
37. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000 Sep; 31: 803-5
38. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyspipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004 Mar 1; 35 (3): 239-52
39. Van Loon K. Safety of high doses of recombinant human growth hormone. Horm Res 1998; 49 Suppl. 2: 78-81
40. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382-95
41. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf 2002; 25 (3): 199-212
42. Par Pharmaceutical Companies Inc. Megace ES prescribing information [online]. Available from URL: http://www.parpharm.com/pdf/megace/ megace_es_pi_final.pdf [Accessed 2005 Dec 8]
43. Solvay Pharmaceuticals Inc. Marinol prescribing information [online]. Available from URL: http://www.unimed.com/pdfs/Marinol.pdf [Accessed 2005 Dec 8]
44. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol Acetate in Patients with AIDS-related Cachexia. Ann Intern Med 1994 Sep; 121 (6): 393-9
45. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994 Sep; 121 (6): 400-8
46. Rietschel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 1240-4
47. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with AIDS wasting syndrome. Ann Intern Med 1998; 129: 18-26
48. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000 Feb; 283 (6): 763-70
49. Miller K, Corcoran C, Armstrong C, et al. Trandsdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998; 83 (8): 2717-25
50. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999; 281: 1282-90
51. Mulligan K, Zackin R, Clark RA, et al. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss. Arch Intern Med 2005; 165: 578-85
52. Hengge UR, Stocks K, Wiehler H, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 2003; 17: 699-710
53. Moyle GJ, Schoelles K, Fahrbach K, et al. Efficacy of selected treatments of HIV wasting. J Acquir Immune Defic Syndr 2004 Dec; 37 Suppl. 5: S262-76
54. Kakuda TN. Somatropin for treating AIDS-related wasting syndrome. Am J Health Syst Pharm 1997 Nov 15; 54 (22): 2618-20